The urogenital system and the menopause

被引:77
作者
Calleja-Agius, J. [1 ,2 ]
Brincat, M. P. [3 ]
机构
[1] Univ Malta, Mater Dei Hosp, Dept Obstet & Gynaecol, Msida, Malta
[2] Univ Malta, Dept Anat, Msida, Malta
[3] Mater Dei Hosp, Dept Obstet & Gynaecol, L Imsida, Malta
关键词
UROGENITAL ATROPHY; ESTROGEN; GENITOURINARY SYNDROME OF MENOPAUSE; STRESS URINARY INCONTINENCE; HORMONE REPLACEMENT THERAPY; VAGINAL RING; POSTMENOPAUSAL WOMEN; RECEPTOR; ATROPHY; MANAGEMENT; HEALTH; VULVAR; CREAM; FLORA;
D O I
10.3109/13697137.2015.1078206
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The major cause of urogenital atrophy in menopausal women is estrogen loss. The symptoms are usually progressive in nature and deteriorate with time from the menopausal transition. The most prevalent urogenital symptoms are vaginal dryness, vaginal irritation and itching. The genitourinary syndrome of menopause includes vulvovaginal atrophy and the postmenopausal modifications of the lower urinary tract. Dyspareunia and vaginal bleeding from fragile atrophic skin are common problems. Other urogenital complaints include frequency, nocturia, urgency, stress urinary incontinence and urinary tract infections. Atrophic changes of the vulva, vagina and lower urinary tract can have a large impact on the quality of life of the menopausal woman. However, hormonal and non-hormonal treatments can provide patients with the solution to regain the previous level of function. Therefore, clinicians should sensitively question and examine menopausal women, in order to correctly identify the pattern of changes in urogenital atrophy and manage them appropriately.
引用
收藏
页码:18 / 22
页数:5
相关论文
共 40 条
[11]   Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the hormones and urogenital therapy committee [J].
Cardozo, L ;
Bachmann, G ;
McClish, D ;
Fonda, D ;
Birgerson, L .
OBSTETRICS AND GYNECOLOGY, 1998, 92 (04) :722-727
[12]   Special considerations in premenopausal and postmenopausal women with symptoms of overactive bladder [J].
Cardozo, L ;
Robinson, D .
UROLOGY, 2002, 60 (5A) :64-71
[13]   Estrogenic effects of a Kampo formula, Tokishakuyakusan, in parous ovariectomized rats [J].
Chung, Mi Hwa ;
Suzuki, Sawako ;
Nishihara, Tsutomu ;
Hattori, Masao .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2008, 31 (06) :1145-1149
[14]  
Cortes-Bonilla M, 2015, GYNECOL ENDOCRINOL
[15]   Global Consensus Statement on Menopausal Hormone Therapy [J].
de Villiers, T. J. ;
Gass, M. L. S. ;
Haines, C. J. ;
Hall, J. E. ;
Lobo, R. A. ;
Pierroz, D. D. ;
Rees, M. .
CLIMACTERIC, 2013, 16 (02) :203-204
[16]   Hormone Replacement Therapy and Messenger RNA Expression of Estrogen Receptor Coregulators after Exercise in Postmenopausal Women [J].
Dieli-Conwright, Christina M. ;
Spektor, Tanya M. ;
Rice, Judd C. ;
Sattler, Fred R. ;
Schroeder, E. Todd .
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2010, 42 (03) :422-429
[17]  
Domoney C, 2014, WOMENS HEALTH, V10, P191, DOI [10.2217/WHE.14.9, 10.2217/whe.14.9]
[18]   Lifetime changes in the vulva and vagina [J].
Farage M. ;
Maibach H. .
Archives of Gynecology and Obstetrics, 2006, 273 (4) :195-202
[19]  
Gambacciani M, 2015, MINERVA GINECOL, V67, P97
[20]   The role of estrogen supplementation in lower urinary tract dysfunction [J].
Hextall, A ;
Cardozo, L .
INTERNATIONAL UROGYNECOLOGY JOURNAL, 2001, 12 (04) :258-261